Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesEptifibatide: The evidence for its role in the management of acute coronary syndromes
Core Evidence, 08/05/09
Shah I et al. – Several large, randomized controlled trials show that eptifibatide as adjunctive therapy to standard care in patients with non–ST segment elevation acute coronary syndrome is associated with a significant reduction in the incidence of death or myocardial infarction. Data are limited regarding the use of eptifibatide in patients with ST segment elevation myocardial infarction. Cost–effectiveness analysis indicates that eptifibatide is associated with a favorable cost–effectiveness ratio relative to standard care. According to US cost–effectiveness analysis about 70% of the acquisition costs of eptifibatide are offset by the reduced medical resource consumption during the first year. Eptifibatide was well tolerated in most of the trials. Bleeding is the most commonly reported adverse event, with most major bleeding episodes occurring at the vascular access site. Major intracranial bleeds, stroke, or profound thrombocytopenia rarely occurred during eptifibatide treatment.
Related Articles
Acute Coronary Syndromes: Diagnosis and Management, Part II
Mayo Clinic Proceedings, 11/03/09
Relevance Score: 83%
Activated factor XII type A and B-type natriuretic peptide are complementary and incremental predictors of mortality in patients following admission with acute coronary syndrome
Blood Coagulation & Fibrinolysis, 11/03/09
Relevance Score: 83%
Endogenous tissue plasminogen activator and risk of recurrent cardiac events after an acute coronary syndrome in the MIRACL study
Atherosclerosis, 10/13/09
Relevance Score: 83%
Effects of Nordic Walking training on exercise capacity and fitness in men participating in early, short-term inpatient cardiac rehabilitation after an acute coronary syndrome — a controlled trial
Clinical Rehabilitation, 11/12/09
Relevance Score: 82%
Management of acute coronary syndrome in a case of Behcets disease
Blood Coagulation & Fibrinolysis, 11/03/09
Relevance Score: 82%
Today in Cardiac/Hypertension...keeping you current
Receive free subspecialty "5-minute updates" via email
Vernakalant hydrochloride for the treatment of atrial fibrillation
Expert Opinion on Investigational Drugs, 11/30/09
The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences
Vascular Health and Risk Management, 11/30/09
Low-Density Lipoprotein Cholesterol Reduction and Goal Achievement With Ezetimibe/Simvastatin Versus Atorvastatin or Rosuvastatin in Patients With Diabetes, Metabolic Syndrome, or Neither Disease, Stratified By National Cholesterol Education Program Risk Category
Metabolic Syndrome and Related Disorders, 11/30/09
Sponsor
Article Search
Sponsor